ISS national lab (ONCOLINX) mission integration and operation services. The proposed flight experiment plans to develop a new azonafide derivative that generates highly potent and highly selective…
Ended Awarded Last action
- Contract number
- NNJ15GU43T
- Awardee
-
The Regents Of The University Of Colorado UEI SPVKK1RC2MZ3
- Awarding agency
-
Johnson Space Center
National Aeronautics and Space Administration
- Obligated
- $368,400
Award facts
- Opportunity
-
- ISS NRA Mission Partnerships: CPF, OCO-3, SAGE III Special Notice · Posted Aug 11, 2025
- Contract value 100% obligated
- $368,400.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Boulder, CO 80303, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $368,400 |
About this award
This is a firm fixed-price delivery order awarded by the Johnson Space Center to The Regents of the University of Colorado, doing business as the University of Colorado Office of Contracts and Grants Division, for ISS National Lab mission integration and operation services. The proposed experiment plans to develop a new cancer drug conjugate and characterize its efficacy and metabolism in a microgravity environment on the International Space Station. The $368,400 contract has a performance period ending on December 31, 2017. The University of Colorado is an accredited public research university with expertise in conducting fundamental research across science, technology, engineering, and mathematics disciplines for federal agencies like NASA, the Department of Defense, and NOAA. This award was not set aside for any specific business type.
Description
ISS national lab (ONCOLINX) mission integration and operation services. The proposed flight experiment plans to develop a new azonafide derivative that generates highly potent and highly selective cytotoxic conjugates upon coupling to antibodies that bind to receptors exclusively expressed on cancer cells. These conjugates will be characterized in a microgravity environment on the ISS. The efficacy and metabolism of the drug will be determined in a low shear microgravity environment that allows cells to grow in a 3-dimensional, spheroid structure which more closely resembles how cancer cells grow in the body. This investigation could potentially accelerate the development of targeted therapies that redefine the paradigm of cancer treatment. The cancer cell line plus a positive and negative control will be frozen and flown to the ISS via cold stowage assets.
Quick answers
Who was awarded contract NNJ15GU43T?
NNJ15GU43T was awarded to The Regents Of The University Of Colorado by Johnson Space Center (National Aeronautics and Space Administration) on September 18, 2015.
How much is contract NNJ15GU43T worth?
The government has obligated $368,400 on NNJ15GU43T.
Is contract NNJ15GU43T an order under another contract?
Yes. NNJ15GU43T is a delivery order under NNJ15GK01C, an indefinite delivery contract.
Was contract NNJ15GU43T competed?
The extent of competition for NNJ15GU43T was full and open competition. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award